Navigation Links
ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
Date:6/10/2008

ourable features the level of efficacy and security in transfusion medicine, both representing the foundation in all medical care, and reduces costs. The product is used to treat complex and isolated coagulation disorders - both congenital and acquired - where no specific coagulation factor concentrate is available, and thrombotic thrombocytopenic purpura ("TTP") - usually in conjunction with plasma exchange. Octaplas(R) is fully licensed in 29 countries worldwide, and roughly 6 million bags have been used successfully to treat approximately 2 million patients around the world since 1991.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the UK, the US and Canada, manufacturing facilities in the UK and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Prometic provides information for its Annual and Special Meeting of Shareholders
2. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
3. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
4. Prometic to present at the American Chemical Society
5. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
6. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
7. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
8. ProMetic provides business update - Over $35 million worth of business secured in January
9. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
10. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
11. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary commercial focus on ... granted a Type C meeting with the U.S. Food ... be held in February 2015.  During this meeting the ...
(Date:12/17/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, announced today its presentation at the ... San Francisco, CA. ... will present on Monday, January 12, 2015, at 9:00 ... webcast live and may be accessed from the "Webcasts ...
(Date:12/15/2014)... TIKVAH, Israel , Dec. 15, 2014 ... ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd. was awarded a grant of approximately ... of the Chief Scientist (OCS).  This is the eighth ... support from the Office of the Chief Scientist, which ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ) ... and investor conference presentations and third,quarter 2008 earnings ... Meeting in Washington D.C. from,October 25 through October ... data in posters and an oral presentation pertaining ...
... Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), ... viral,infections, today announced that updated preliminary data from the first,stage of ...
... product ... development for NewCardio, SANTA CLARA, Calif., ... diagnostic and services company, today,announced Dorin Panescu, PhD, has agreed ... Research and Development, effective,October 20. Dr. Panescu joins NewCardio from ...
Cached Biology Technology:Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call 2Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4Dorin Panescu Named NewCardio's Chief Technical Officer 2Dorin Panescu Named NewCardio's Chief Technical Officer 3Dorin Panescu Named NewCardio's Chief Technical Officer 4
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... Neuherberg, February 10., 2010. Eczema in early childhood ... This is a key finding of a prospective birth ... contributed. In cooperation with colleagues of Ludwig-Maximilians-Universitt (LMU), Technische ... this study followed 5,991 children who were born between ...
... by a top ecological,forecaster says it is harder than ... systems will occur -- a worrisome,finding for scientists trying ... into an irreparable global disaster. "Many scientists are ... natural systems, in hopes of forestalling those changes,or improving ...
... off attacks by Hessian fly larvae by essentially destroying the ... a study by Purdue University and the U.S. Department of ... intestines - were observed in three different feeding situations. Larvae ... given nothing to eat showed no damage to the midgut, ...
Cached Biology News:Eczema in early childhood and psychological problems 2New UC Davis study: Climate 'tipping points' may arrive without warning, says top forecaster 2Resistant wheat goes for the gut to protect against Hessian flies 2